Associated Papers
Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.
Lan Y et al.
British Journal of Cancer, 2025
40588514 (PubMed )
Supplement: 41416_2025_3098_MOESM1_ESM.pdf
ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance.
Vacarean-Trandafir IC et al.
Molecular Biology Reports, 2019
Outcomes of 219 chronic myeloid leukaemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations.
Xue M et al.
International Journal of Laboratory Hematology, 2019
Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM et al.
Cancer Biology & Therapy, 2017
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Parker WT et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2011
Select a paper to view details